We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: June 7, 2011
Last Update Posted: February 9, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Ministry of Health, France
Cytheris, Inc.
Information provided by (Responsible Party):
Centre Leon Berard
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2014
  Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
27. Miguel-Angel Perales, Jenna D. Goldberg,, Leuren Lechner Jianda Yuan, Esperanza Papadopoulos, James W. Young, Ann A. Jakubowski, Guenther Koehne, Humilidad Gallardo, Ryan Kendle, Cailian Liu, Teresa Rasalan, Yinyan Xu, Bushra Zaidi, Jedd D Wolchok, Therese Croughs, Michel Morre, Molly Maloy, Glenn Heller and Marcel R.M. van den Brink. Recombinant Human Interleukin-7 (CYT107) Enhances CD4 and CD8 T Cell Recovery Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant In Patients with Myeloid Malignancies Oral and Poster Abstracts Oral Session: ASH 2010 Meeting.